#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=The current methods using microwave urethra heating without cooling have been found to treat to a depth of about 0.6 cm and a length of about 4.5 cm.
1-1	0-3	The	_	_	
1-2	4-11	current	_	_	
1-3	12-19	methods	_	_	
1-4	20-25	using	_	_	
1-5	26-35	microwave	_	_	
1-6	36-43	urethra	_	_	
1-7	44-51	heating	_	_	
1-8	52-59	without	_	_	
1-9	60-67	cooling	_	_	
1-10	68-72	have	_	_	
1-11	73-77	been	_	_	
1-12	78-83	found	_	_	
1-13	84-86	to	_	_	
1-14	87-92	treat	_	_	
1-15	93-95	to	_	_	
1-16	96-97	a	_	_	
1-17	98-103	depth	_	_	
1-18	104-106	of	_	_	
1-19	107-112	about	_	_	
1-20	113-116	0.6	_	_	
1-21	117-119	cm	_	_	
1-22	120-123	and	_	_	
1-23	124-125	a	_	_	
1-24	126-132	length	_	_	
1-25	133-135	of	_	_	
1-26	136-141	about	_	_	
1-27	142-145	4.5	_	_	
1-28	146-148	cm	_	_	
1-29	148-149	.	_	_	

#Text=This results in a treated volume of about 9 cm.sup.3 for a mass of 9 grams.
2-1	150-154	This	_	_	
2-2	155-162	results	_	_	
2-3	163-165	in	_	_	
2-4	166-167	a	_	_	
2-5	168-175	treated	_	_	
2-6	176-182	volume	_	_	
2-7	183-185	of	_	_	
2-8	186-191	about	_	_	
2-9	192-193	9	_	_	
2-10	194-200	cm.sup	_	_	
2-11	200-202	.3	_	_	
2-12	203-206	for	_	_	
2-13	207-208	a	_	_	
2-14	209-213	mass	_	_	
2-15	214-216	of	_	_	
2-16	217-218	9	_	_	
2-17	219-224	grams	_	_	
2-18	224-225	.	_	_	

#Text=The most common surgical procedure to correct this urinary blockage or retention and other symptoms of benign prostate diseases is the trans-urethral resection of the prostate (TURP).
3-1	226-229	The	_	_	
3-2	230-234	most	_	_	
3-3	235-241	common	_	_	
3-4	242-250	surgical	_	_	
3-5	251-260	procedure	_	_	
3-6	261-263	to	_	_	
3-7	264-271	correct	_	_	
3-8	272-276	this	_	_	
3-9	277-284	urinary	_	_	
3-10	285-293	blockage	_	_	
3-11	294-296	or	_	_	
3-12	297-306	retention	_	_	
3-13	307-310	and	_	_	
3-14	311-316	other	_	_	
3-15	317-325	symptoms	_	_	
3-16	326-328	of	_	_	
3-17	329-335	benign	_	_	
3-18	336-344	prostate	_	_	
3-19	345-353	diseases	_	_	
3-20	354-356	is	_	_	
3-21	357-360	the	_	_	
3-22	361-375	trans-urethral	_	_	
3-23	376-385	resection	_	_	
3-24	386-388	of	_	_	
3-25	389-392	the	_	_	
3-26	393-401	prostate	_	_	
3-27	402-403	(	_	_	
3-28	403-407	TURP	_	_	
3-29	407-408	)	_	_	
3-30	408-409	.	_	_	

#Text=The TURP procedure normally involves the surgical removal of about 15 to 20 grams of prostate tissue along the urethra passage inside the length of the prostate gland.
4-1	410-413	The	_	_	
4-2	414-418	TURP	_	_	
4-3	419-428	procedure	_	_	
4-4	429-437	normally	_	_	
4-5	438-446	involves	_	_	
4-6	447-450	the	_	_	
4-7	451-459	surgical	_	_	
4-8	460-467	removal	_	_	
4-9	468-470	of	_	_	
4-10	471-476	about	_	_	
4-11	477-479	15	_	_	
4-12	480-482	to	_	_	
4-13	483-485	20	_	_	
4-14	486-491	grams	_	_	
4-15	492-494	of	_	_	
4-16	495-503	prostate	_	_	
4-17	504-510	tissue	_	_	
4-18	511-516	along	_	_	
4-19	517-520	the	_	_	
4-20	521-528	urethra	_	_	
4-21	529-536	passage	_	_	
4-22	537-543	inside	_	_	
4-23	544-547	the	_	_	
4-24	548-554	length	_	_	
4-25	555-557	of	_	_	
4-26	558-561	the	_	_	
4-27	562-570	prostate	_	_	
4-28	571-576	gland	_	_	
4-29	576-577	.	_	_	

#Text=Thus, less tissue is treated by the heat treatment in the first session, than is surgically removed to resolve the symptoms.
5-1	578-582	Thus	_	_	
5-2	582-583	,	_	_	
5-3	584-588	less	_	_	
5-4	589-595	tissue	_	_	
5-5	596-598	is	_	_	
5-6	599-606	treated	_	_	
5-7	607-609	by	_	_	
5-8	610-613	the	_	_	
5-9	614-618	heat	_	_	
5-10	619-628	treatment	_	_	
5-11	629-631	in	_	_	
5-12	632-635	the	_	_	
5-13	636-641	first	_	_	
5-14	642-649	session	_	_	
5-15	649-650	,	_	_	
5-16	651-655	than	_	_	
5-17	656-658	is	_	_	
5-18	659-669	surgically	_	_	
5-19	670-677	removed	_	_	
5-20	678-680	to	_	_	
5-21	681-688	resolve	_	_	
5-22	689-692	the	_	_	
5-23	693-701	symptoms	_	_	
5-24	701-702	.	_	_	

#Text=After the first treatment with current methods, some of the prostate tissues become necrotic and begin to recede by the body's removal of the dead cells.
6-1	703-708	After	_	_	
6-2	709-712	the	_	_	
6-3	713-718	first	_	_	
6-4	719-728	treatment	_	_	
6-5	729-733	with	_	_	
6-6	734-741	current	_	_	
6-7	742-749	methods	_	_	
6-8	749-750	,	_	_	
6-9	751-755	some	_	_	
6-10	756-758	of	_	_	
6-11	759-762	the	_	_	
6-12	763-771	prostate	_	_	
6-13	772-779	tissues	_	_	
6-14	780-786	become	_	_	
6-15	787-795	necrotic	_	_	
6-16	796-799	and	_	_	
6-17	800-805	begin	_	_	
6-18	806-808	to	_	_	
6-19	809-815	recede	_	_	
6-20	816-818	by	_	_	
6-21	819-822	the	_	_	
6-22	823-829	body's	_	_	
6-23	830-837	removal	_	_	
6-24	838-840	of	_	_	
6-25	841-844	the	_	_	
6-26	845-849	dead	_	_	
6-27	850-855	cells	_	_	
6-28	855-856	.	_	_	

#Text=By the next heat treatment several days later, some of the original tissue is most likely not present.
7-1	857-859	By	_	_	
7-2	860-863	the	_	_	
7-3	864-868	next	_	_	
7-4	869-873	heat	_	_	
7-5	874-883	treatment	_	_	
7-6	884-891	several	_	_	
7-7	892-896	days	_	_	
7-8	897-902	later	_	_	
7-9	902-903	,	_	_	
7-10	904-908	some	_	_	
7-11	909-911	of	_	_	
7-12	912-915	the	_	_	
7-13	916-924	original	_	_	
7-14	925-931	tissue	_	_	
7-15	932-934	is	_	_	
7-16	935-939	most	_	_	
7-17	940-946	likely	_	_	
7-18	947-950	not	_	_	
7-19	951-958	present	_	_	
7-20	958-959	.	_	_	

#Text=This enables a second heat treatment to adequately heat tissues which were beyond the heating depth of the first treatment.
8-1	960-964	This	_	_	
8-2	965-972	enables	_	_	
8-3	973-974	a	_	_	
8-4	975-981	second	_	_	
8-5	982-986	heat	_	_	
8-6	987-996	treatment	_	_	
8-7	997-999	to	_	_	
8-8	1000-1010	adequately	_	_	
8-9	1011-1015	heat	_	_	
8-10	1016-1023	tissues	_	_	
8-11	1024-1029	which	_	_	
8-12	1030-1034	were	_	_	
8-13	1035-1041	beyond	_	_	
8-14	1042-1045	the	_	_	
8-15	1046-1053	heating	_	_	
8-16	1054-1059	depth	_	_	
8-17	1060-1062	of	_	_	
8-18	1063-1066	the	_	_	
8-19	1067-1072	first	_	_	
8-20	1073-1082	treatment	_	_	
8-21	1082-1083	.	_	_	

#Text=Thus, repeated heating treatments are required to eventually treat sufficient tissues to obtain the therapeutic effect and benefit as is provided by the surgical method of (TURP).
9-1	1084-1088	Thus	_	_	
9-2	1088-1089	,	_	_	
9-3	1090-1098	repeated	_	_	
9-4	1099-1106	heating	_	_	
9-5	1107-1117	treatments	_	_	
9-6	1118-1121	are	_	_	
9-7	1122-1130	required	_	_	
9-8	1131-1133	to	_	_	
9-9	1134-1144	eventually	_	_	
9-10	1145-1150	treat	_	_	
9-11	1151-1161	sufficient	_	_	
9-12	1162-1169	tissues	_	_	
9-13	1170-1172	to	_	_	
9-14	1173-1179	obtain	_	_	
9-15	1180-1183	the	_	_	
9-16	1184-1195	therapeutic	_	_	
9-17	1196-1202	effect	_	_	
9-18	1203-1206	and	_	_	
9-19	1207-1214	benefit	_	_	
9-20	1215-1217	as	_	_	
9-21	1218-1220	is	_	_	
9-22	1221-1229	provided	_	_	
9-23	1230-1232	by	_	_	
9-24	1233-1236	the	_	_	
9-25	1237-1245	surgical	_	_	
9-26	1246-1252	method	_	_	
9-27	1253-1255	of	_	_	
9-28	1256-1257	(	_	_	
9-29	1257-1261	TURP	_	_	
9-30	1261-1262	)	_	_	
9-31	1262-1263	.	_	_	

#Text=By using the circulating fluid cooling within the urethra during microwave treatment, the depth of the therapeutic heating is increased because more power can be radiated without causing excessive temperatures.
10-1	1264-1266	By	_	_	
10-2	1267-1272	using	_	_	
10-3	1273-1276	the	_	_	
10-4	1277-1288	circulating	_	_	
10-5	1289-1294	fluid	_	_	
10-6	1295-1302	cooling	_	_	
10-7	1303-1309	within	_	_	
10-8	1310-1313	the	_	_	
10-9	1314-1321	urethra	_	_	
10-10	1322-1328	during	_	_	
10-11	1329-1338	microwave	_	_	
10-12	1339-1348	treatment	_	_	
10-13	1348-1349	,	_	_	
10-14	1350-1353	the	_	_	
10-15	1354-1359	depth	_	_	
10-16	1360-1362	of	_	_	
10-17	1363-1366	the	_	_	
10-18	1367-1378	therapeutic	_	_	
10-19	1379-1386	heating	_	_	
10-20	1387-1389	is	_	_	
10-21	1390-1399	increased	_	_	
10-22	1400-1407	because	_	_	
10-23	1408-1412	more	_	_	
10-24	1413-1418	power	_	_	
10-25	1419-1422	can	_	_	
10-26	1423-1425	be	_	_	
10-27	1426-1434	radiated	_	_	
10-28	1435-1442	without	_	_	
10-29	1443-1450	causing	_	_	
10-30	1451-1460	excessive	_	_	
10-31	1461-1473	temperatures	_	_	
10-32	1473-1474	.	_	_	

#Text=Excessive temperature would certainly contribute to power limiting pain, and may contribute to undesirable toxicity.
11-1	1475-1484	Excessive	_	_	
11-2	1485-1496	temperature	_	_	
11-3	1497-1502	would	_	_	
11-4	1503-1512	certainly	_	_	
11-5	1513-1523	contribute	_	_	
11-6	1524-1526	to	_	_	
11-7	1527-1532	power	_	_	
11-8	1533-1541	limiting	_	_	
11-9	1542-1546	pain	_	_	
11-10	1546-1547	,	_	_	
11-11	1548-1551	and	_	_	
11-12	1552-1555	may	_	_	
11-13	1556-1566	contribute	_	_	
11-14	1567-1569	to	_	_	
11-15	1570-1581	undesirable	_	_	
11-16	1582-1590	toxicity	_	_	
11-17	1590-1591	.	_	_	

#Text=The volume of tissue which can therefore be treated to therapeutic temperature levels in the first treatment is about 22 cm.sup.3, which is a mass of 22 grams of tissue.
12-1	1592-1595	The	_	_	
12-2	1596-1602	volume	_	_	
12-3	1603-1605	of	_	_	
12-4	1606-1612	tissue	_	_	
12-5	1613-1618	which	_	_	
12-6	1619-1622	can	_	_	
12-7	1623-1632	therefore	_	_	
12-8	1633-1635	be	_	_	
12-9	1636-1643	treated	_	_	
12-10	1644-1646	to	_	_	
12-11	1647-1658	therapeutic	_	_	
12-12	1659-1670	temperature	_	_	
12-13	1671-1677	levels	_	_	
12-14	1678-1680	in	_	_	
12-15	1681-1684	the	_	_	
12-16	1685-1690	first	_	_	
12-17	1691-1700	treatment	_	_	
12-18	1701-1703	is	_	_	
12-19	1704-1709	about	_	_	
12-20	1710-1712	22	_	_	
12-21	1713-1719	cm.sup	_	_	
12-22	1719-1721	.3	_	_	
12-23	1721-1722	,	_	_	
12-24	1723-1728	which	_	_	
12-25	1729-1731	is	_	_	
12-26	1732-1733	a	_	_	
12-27	1734-1738	mass	_	_	
12-28	1739-1741	of	_	_	
12-29	1742-1744	22	_	_	
12-30	1745-1750	grams	_	_	
12-31	1751-1753	of	_	_	
12-32	1754-1760	tissue	_	_	
12-33	1760-1761	.	_	_	

#Text=This is slightly over that normally resected by a TURP.
13-1	1762-1766	This	_	_	
13-2	1767-1769	is	_	_	
13-3	1770-1778	slightly	_	_	
13-4	1779-1783	over	_	_	
13-5	1784-1788	that	_	_	
13-6	1789-1797	normally	_	_	
13-7	1798-1806	resected	_	_	
13-8	1807-1809	by	_	_	
13-9	1810-1811	a	_	_	
13-10	1812-1816	TURP	_	_	
13-11	1816-1817	.	_	_	

#Text=Thus, the method of cooling within the prostate urethra enables the complete target tissue mass along the prostate urethra to be adequately heated in just one heating session.
14-1	1818-1822	Thus	_	_	
14-2	1822-1823	,	_	_	
14-3	1824-1827	the	_	_	
14-4	1828-1834	method	_	_	
14-5	1835-1837	of	_	_	
14-6	1838-1845	cooling	_	_	
14-7	1846-1852	within	_	_	
14-8	1853-1856	the	_	_	
14-9	1857-1865	prostate	_	_	
14-10	1866-1873	urethra	_	_	
14-11	1874-1881	enables	_	_	
14-12	1882-1885	the	_	_	
14-13	1886-1894	complete	_	_	
14-14	1895-1901	target	_	_	
14-15	1902-1908	tissue	_	_	
14-16	1909-1913	mass	_	_	
14-17	1914-1919	along	_	_	
14-18	1920-1923	the	_	_	
14-19	1924-1932	prostate	_	_	
14-20	1933-1940	urethra	_	_	
14-21	1941-1943	to	_	_	
14-22	1944-1946	be	_	_	
14-23	1947-1957	adequately	_	_	
14-24	1958-1964	heated	_	_	
14-25	1965-1967	in	_	_	
14-26	1968-1972	just	_	_	
14-27	1973-1976	one	_	_	
14-28	1977-1984	heating	_	_	
14-29	1985-1992	session	_	_	
14-30	1992-1993	.	_	_	

#Text=To provide for a repeatable and safe therapy, it is important to provide sufficient power to reach these therapeutic levels and maintain these temperatures for typically about 60 minutes.
15-1	1994-1996	To	_	_	
15-2	1997-2004	provide	_	_	
15-3	2005-2008	for	_	_	
15-4	2009-2010	a	_	_	
15-5	2011-2021	repeatable	_	_	
15-6	2022-2025	and	_	_	
15-7	2026-2030	safe	_	_	
15-8	2031-2038	therapy	_	_	
15-9	2038-2039	,	_	_	
15-10	2040-2042	it	_	_	
15-11	2043-2045	is	_	_	
15-12	2046-2055	important	_	_	
15-13	2056-2058	to	_	_	
15-14	2059-2066	provide	_	_	
15-15	2067-2077	sufficient	_	_	
15-16	2078-2083	power	_	_	
15-17	2084-2086	to	_	_	
15-18	2087-2092	reach	_	_	
15-19	2093-2098	these	_	_	
15-20	2099-2110	therapeutic	_	_	
15-21	2111-2117	levels	_	_	
15-22	2118-2121	and	_	_	
15-23	2122-2130	maintain	_	_	
15-24	2131-2136	these	_	_	
15-25	2137-2149	temperatures	_	_	
15-26	2150-2153	for	_	_	
15-27	2154-2163	typically	_	_	
15-28	2164-2169	about	_	_	
15-29	2170-2172	60	_	_	
15-30	2173-2180	minutes	_	_	
15-31	2180-2181	.	_	_	

#Text=Higher temperatures would enable shorter times, but patient pain may prevent temperatures in excess of about 48.degree.
16-1	2182-2188	Higher	_	_	
16-2	2189-2201	temperatures	_	_	
16-3	2202-2207	would	_	_	
16-4	2208-2214	enable	_	_	
16-5	2215-2222	shorter	_	_	
16-6	2223-2228	times	_	_	
16-7	2228-2229	,	_	_	
16-8	2230-2233	but	_	_	
16-9	2234-2241	patient	_	_	
16-10	2242-2246	pain	_	_	
16-11	2247-2250	may	_	_	
16-12	2251-2258	prevent	_	_	
16-13	2259-2271	temperatures	_	_	
16-14	2272-2274	in	_	_	
16-15	2275-2281	excess	_	_	
16-16	2282-2284	of	_	_	
16-17	2285-2290	about	_	_	
16-18	2291-2293	48	_	_	
16-19	2293-2294	.	_	_	
16-20	2294-2300	degree	_	_	
16-21	2300-2301	.	_	_	

#Text=C.
17-1	2302-2303	C	_	_	
17-2	2303-2304	.	_	_	

#Text=It is possible to incorporate temperature sensors in the applicator to attempt to estimate tissue temperature, but this would also require monitoring to the radiated power and require performing occasional tissue cool-down measurements to estimate the effect of blood flow, tissue thermal conduction, and bolus cooling effects.
18-1	2305-2307	It	_	_	
18-2	2308-2310	is	_	_	
18-3	2311-2319	possible	_	_	
18-4	2320-2322	to	_	_	
18-5	2323-2334	incorporate	_	_	
18-6	2335-2346	temperature	_	_	
18-7	2347-2354	sensors	_	_	
18-8	2355-2357	in	_	_	
18-9	2358-2361	the	_	_	
18-10	2362-2372	applicator	_	_	
18-11	2373-2375	to	_	_	
18-12	2376-2383	attempt	_	_	
18-13	2384-2386	to	_	_	
18-14	2387-2395	estimate	_	_	
18-15	2396-2402	tissue	_	_	
18-16	2403-2414	temperature	_	_	
18-17	2414-2415	,	_	_	
18-18	2416-2419	but	_	_	
18-19	2420-2424	this	_	_	
18-20	2425-2430	would	_	_	
18-21	2431-2435	also	_	_	
18-22	2436-2443	require	_	_	
18-23	2444-2454	monitoring	_	_	
18-24	2455-2457	to	_	_	
18-25	2458-2461	the	_	_	
18-26	2462-2470	radiated	_	_	
18-27	2471-2476	power	_	_	
18-28	2477-2480	and	_	_	
18-29	2481-2488	require	_	_	
18-30	2489-2499	performing	_	_	
18-31	2500-2510	occasional	_	_	
18-32	2511-2517	tissue	_	_	
18-33	2518-2527	cool-down	_	_	
18-34	2528-2540	measurements	_	_	
18-35	2541-2543	to	_	_	
18-36	2544-2552	estimate	_	_	
18-37	2553-2556	the	_	_	
18-38	2557-2563	effect	_	_	
18-39	2564-2566	of	_	_	
18-40	2567-2572	blood	_	_	
18-41	2573-2577	flow	_	_	
18-42	2577-2578	,	_	_	
18-43	2579-2585	tissue	_	_	
18-44	2586-2593	thermal	_	_	
18-45	2594-2604	conduction	_	_	
18-46	2604-2605	,	_	_	
18-47	2606-2609	and	_	_	
18-48	2610-2615	bolus	_	_	
18-49	2616-2623	cooling	_	_	
18-50	2624-2631	effects	_	_	
18-51	2631-2632	.	_	_	

#Text=This is not expected to be as reliable in all patients as compared with a direct temperature measurement.
19-1	2633-2637	This	_	_	
19-2	2638-2640	is	_	_	
19-3	2641-2644	not	_	_	
19-4	2645-2653	expected	_	_	
19-5	2654-2656	to	_	_	
19-6	2657-2659	be	_	_	
19-7	2660-2662	as	_	_	
19-8	2663-2671	reliable	_	_	
19-9	2672-2674	in	_	_	
19-10	2675-2678	all	_	_	
19-11	2679-2687	patients	_	_	
19-12	2688-2690	as	_	_	
19-13	2691-2699	compared	_	_	
19-14	2700-2704	with	_	_	
19-15	2705-2706	a	_	_	
19-16	2707-2713	direct	_	_	
19-17	2714-2725	temperature	_	_	
19-18	2726-2737	measurement	_	_	
19-19	2737-2738	.	_	_	

#Text=The preferred method to measure the prostate tissue temperature is by using the heating applicator in a receive mode to direct the thermal noise in the heated prostate region into a microwave or US radiometer.
20-1	2739-2742	The	*[1]	24-1[2_1]	
20-2	2743-2752	preferred	*[1]	_	
20-3	2753-2759	method	*[1]	_	
20-4	2760-2762	to	*[1]	_	
20-5	2763-2770	measure	*[1]	_	
20-6	2771-2774	the	*[1]	_	
20-7	2775-2783	prostate	*[1]	_	
20-8	2784-2790	tissue	*[1]	_	
20-9	2791-2802	temperature	*[1]	_	
20-10	2803-2805	is	*[1]	_	
20-11	2806-2808	by	*[1]	_	
20-12	2809-2814	using	*[1]	_	
20-13	2815-2818	the	*[1]	_	
20-14	2819-2826	heating	*[1]	_	
20-15	2827-2837	applicator	*[1]	_	
20-16	2838-2840	in	*[1]	_	
20-17	2841-2842	a	*[1]	_	
20-18	2843-2850	receive	*[1]	_	
20-19	2851-2855	mode	*[1]	_	
20-20	2856-2858	to	*[1]	_	
20-21	2859-2865	direct	*[1]	_	
20-22	2866-2869	the	*[1]	_	
20-23	2870-2877	thermal	*[1]	_	
20-24	2878-2883	noise	*[1]	_	
20-25	2884-2886	in	*[1]	_	
20-26	2887-2890	the	*[1]	_	
20-27	2891-2897	heated	*[1]	_	
20-28	2898-2906	prostate	*[1]	_	
20-29	2907-2913	region	*[1]	_	
20-30	2914-2918	into	*[1]	_	
20-31	2919-2920	a	*[1]	_	
20-32	2921-2930	microwave	*[1]	_	
20-33	2931-2933	or	*[1]	_	
20-34	2934-2936	US	*[1]	_	
20-35	2937-2947	radiometer	*[1]	_	
20-36	2947-2948	.	*[1]	_	

#Text=The temperature measurements of the radiometer provide a measurement which is directly related to the temperature within the prostate tissue volume corresponding to the heating volume.
21-1	2949-2952	The	_	_	
21-2	2953-2964	temperature	_	_	
21-3	2965-2977	measurements	_	_	
21-4	2978-2980	of	_	_	
21-5	2981-2984	the	_	_	
21-6	2985-2995	radiometer	_	_	
21-7	2996-3003	provide	_	_	
21-8	3004-3005	a	_	_	
21-9	3006-3017	measurement	_	_	
21-10	3018-3023	which	_	_	
21-11	3024-3026	is	_	_	
21-12	3027-3035	directly	_	_	
21-13	3036-3043	related	_	_	
21-14	3044-3046	to	_	_	
21-15	3047-3050	the	_	_	
21-16	3051-3062	temperature	_	_	
21-17	3063-3069	within	_	_	
21-18	3070-3073	the	_	_	
21-19	3074-3082	prostate	_	_	
21-20	3083-3089	tissue	_	_	
21-21	3090-3096	volume	_	_	
21-22	3097-3110	corresponding	_	_	
21-23	3111-3113	to	_	_	
21-24	3114-3117	the	_	_	
21-25	3118-3125	heating	_	_	
21-26	3126-3132	volume	_	_	
21-27	3132-3133	.	_	_	

#Text=This measurement is comprised of adding the temperature signals from the various tissue cells within the applicator's heating field.
22-1	3134-3138	This	_	_	
22-2	3139-3150	measurement	_	_	
22-3	3151-3153	is	_	_	
22-4	3154-3163	comprised	_	_	
22-5	3164-3166	of	_	_	
22-6	3167-3173	adding	_	_	
22-7	3174-3177	the	_	_	
22-8	3178-3189	temperature	_	_	
22-9	3190-3197	signals	_	_	
22-10	3198-3202	from	_	_	
22-11	3203-3206	the	_	_	
22-12	3207-3214	various	_	_	
22-13	3215-3221	tissue	_	_	
22-14	3222-3227	cells	_	_	
22-15	3228-3234	within	_	_	
22-16	3235-3238	the	_	_	
22-17	3239-3251	applicator's	_	_	
22-18	3252-3259	heating	_	_	
22-19	3260-3265	field	_	_	
22-20	3265-3266	.	_	_	

#Text=Therefore, this measurement is like having thousands of individual temperature points which are measured and then added together to provide an indication of the average temperatures within the heated region.
23-1	3267-3276	Therefore	_	_	
23-2	3276-3277	,	_	_	
23-3	3278-3282	this	_	_	
23-4	3283-3294	measurement	_	_	
23-5	3295-3297	is	_	_	
23-6	3298-3302	like	_	_	
23-7	3303-3309	having	_	_	
23-8	3310-3319	thousands	_	_	
23-9	3320-3322	of	_	_	
23-10	3323-3333	individual	_	_	
23-11	3334-3345	temperature	_	_	
23-12	3346-3352	points	_	_	
23-13	3353-3358	which	_	_	
23-14	3359-3362	are	_	_	
23-15	3363-3371	measured	_	_	
23-16	3372-3375	and	_	_	
23-17	3376-3380	then	_	_	
23-18	3381-3386	added	_	_	
23-19	3387-3395	together	_	_	
23-20	3396-3398	to	_	_	
23-21	3399-3406	provide	_	_	
23-22	3407-3409	an	_	_	
23-23	3410-3420	indication	_	_	
23-24	3421-3423	of	_	_	
23-25	3424-3427	the	_	_	
23-26	3428-3435	average	_	_	
23-27	3436-3448	temperatures	_	_	
23-28	3449-3455	within	_	_	
23-29	3456-3459	the	_	_	
23-30	3460-3466	heated	_	_	
23-31	3467-3473	region	_	_	
23-32	3473-3474	.	_	_	

#Text=This method does not measure the maximum or the minimum temperature in the heated tissue, but provides an accurate measure of the average tissue temperature within the treatment zone.
24-1	3475-3479	This	*[2]	_	
24-2	3480-3486	method	*[2]	_	
24-3	3487-3491	does	_	_	
24-4	3492-3495	not	_	_	
24-5	3496-3503	measure	_	_	
24-6	3504-3507	the	_	_	
24-7	3508-3515	maximum	_	_	
24-8	3516-3518	or	_	_	
24-9	3519-3522	the	_	_	
24-10	3523-3530	minimum	_	_	
24-11	3531-3542	temperature	_	_	
24-12	3543-3545	in	_	_	
24-13	3546-3549	the	_	_	
24-14	3550-3556	heated	_	_	
24-15	3557-3563	tissue	_	_	
24-16	3563-3564	,	_	_	
24-17	3565-3568	but	_	_	
24-18	3569-3577	provides	_	_	
24-19	3578-3580	an	_	_	
24-20	3581-3589	accurate	_	_	
24-21	3590-3597	measure	_	_	
24-22	3598-3600	of	_	_	
24-23	3601-3604	the	_	_	
24-24	3605-3612	average	_	_	
24-25	3613-3619	tissue	_	_	
24-26	3620-3631	temperature	_	_	
24-27	3632-3638	within	_	_	
24-28	3639-3642	the	_	_	
24-29	3643-3652	treatment	_	_	
24-30	3653-3657	zone	_	_	
24-31	3657-3658	.	_	_	

#Text=This new method enables the treatment of benign prostate disease to be efficiently treated with hyperthermia, where the tissue being treated is the same tissue which would have been surgically removed by a TURP.
25-1	3659-3663	This	_	_	
25-2	3664-3667	new	_	_	
25-3	3668-3674	method	_	_	
25-4	3675-3682	enables	_	_	
25-5	3683-3686	the	_	_	
25-6	3687-3696	treatment	_	_	
25-7	3697-3699	of	_	_	
25-8	3700-3706	benign	_	_	
25-9	3707-3715	prostate	_	_	
25-10	3716-3723	disease	_	_	
25-11	3724-3726	to	_	_	
25-12	3727-3729	be	_	_	
25-13	3730-3741	efficiently	_	_	
25-14	3742-3749	treated	_	_	
25-15	3750-3754	with	_	_	
25-16	3755-3767	hyperthermia	_	_	
25-17	3767-3768	,	_	_	
25-18	3769-3774	where	_	_	
25-19	3775-3778	the	_	_	
25-20	3779-3785	tissue	_	_	
25-21	3786-3791	being	_	_	
25-22	3792-3799	treated	_	_	
25-23	3800-3802	is	_	_	
25-24	3803-3806	the	_	_	
25-25	3807-3811	same	_	_	
25-26	3812-3818	tissue	_	_	
25-27	3819-3824	which	_	_	
25-28	3825-3830	would	_	_	
25-29	3831-3835	have	_	_	
25-30	3836-3840	been	_	_	
25-31	3841-3851	surgically	_	_	
25-32	3852-3859	removed	_	_	
25-33	3860-3862	by	_	_	
25-34	3863-3864	a	_	_	
25-35	3865-3869	TURP	_	_	
25-36	3869-3870	.	_	_	

#Text=In many patients there are severe side effects by the TURP procedure such as incontinence, retrograde ejaculation, impotency, and death.
26-1	3871-3873	In	_	_	
26-2	3874-3878	many	_	_	
26-3	3879-3887	patients	_	_	
26-4	3888-3893	there	_	_	
26-5	3894-3897	are	_	_	
26-6	3898-3904	severe	_	_	
26-7	3905-3909	side	_	_	
26-8	3910-3917	effects	_	_	
26-9	3918-3920	by	_	_	
26-10	3921-3924	the	_	_	
26-11	3925-3929	TURP	_	_	
26-12	3930-3939	procedure	_	_	
26-13	3940-3944	such	_	_	
26-14	3945-3947	as	_	_	
26-15	3948-3960	incontinence	_	_	
26-16	3960-3961	,	_	_	
26-17	3962-3972	retrograde	_	_	
26-18	3973-3984	ejaculation	_	_	
26-19	3984-3985	,	_	_	
26-20	3986-3995	impotency	_	_	
26-21	3995-3996	,	_	_	
26-22	3997-4000	and	_	_	
26-23	4001-4006	death	_	_	
26-24	4006-4007	.	_	_	

#Text=It is estimated that between 0.3 to 3% of the patients receiving the TURP surgical procedure die from either the procedure or by other factors related to the procedure.
27-1	4008-4010	It	_	_	
27-2	4011-4013	is	_	_	
27-3	4014-4023	estimated	_	_	
27-4	4024-4028	that	_	_	
27-5	4029-4036	between	_	_	
27-6	4037-4040	0.3	_	_	
27-7	4041-4043	to	_	_	
27-8	4044-4046	3%	_	_	
27-9	4047-4049	of	_	_	
27-10	4050-4053	the	_	_	
27-11	4054-4062	patients	_	_	
27-12	4063-4072	receiving	_	_	
27-13	4073-4076	the	_	_	
27-14	4077-4081	TURP	_	_	
27-15	4082-4090	surgical	_	_	
27-16	4091-4100	procedure	_	_	
27-17	4101-4104	die	_	_	
27-18	4105-4109	from	_	_	
27-19	4110-4116	either	_	_	
27-20	4117-4120	the	_	_	
27-21	4121-4130	procedure	_	_	
27-22	4131-4133	or	_	_	
27-23	4134-4136	by	_	_	
27-24	4137-4142	other	_	_	
27-25	4143-4150	factors	_	_	
27-26	4151-4158	related	_	_	
27-27	4159-4161	to	_	_	
27-28	4162-4165	the	_	_	
27-29	4166-4175	procedure	_	_	
27-30	4175-4176	.	_	_	

#Text=Many patients are poor surgical risks due to their age and poor health.
28-1	4177-4181	Many	_	_	
28-2	4182-4190	patients	_	_	
28-3	4191-4194	are	_	_	
28-4	4195-4199	poor	_	_	
28-5	4200-4208	surgical	_	_	
28-6	4209-4214	risks	_	_	
28-7	4215-4218	due	_	_	
28-8	4219-4221	to	_	_	
28-9	4222-4227	their	_	_	
28-10	4228-4231	age	_	_	
28-11	4232-4235	and	_	_	
28-12	4236-4240	poor	_	_	
28-13	4241-4247	health	_	_	
28-14	4247-4248	.	_	_	

#Text=The use of hyperthermia treatments as described herein, represent a non-surgical alternative therapy for the benign prostate disease.
29-1	4249-4252	The	_	_	
29-2	4253-4256	use	_	_	
29-3	4257-4259	of	_	_	
29-4	4260-4272	hyperthermia	_	_	
29-5	4273-4283	treatments	_	_	
29-6	4284-4286	as	_	_	
29-7	4287-4296	described	_	_	
29-8	4297-4303	herein	_	_	
29-9	4303-4304	,	_	_	
29-10	4305-4314	represent	_	_	
29-11	4315-4316	a	_	_	
29-12	4317-4329	non-surgical	_	_	
29-13	4330-4341	alternative	_	_	
29-14	4342-4349	therapy	_	_	
29-15	4350-4353	for	_	_	
29-16	4354-4357	the	_	_	
29-17	4358-4364	benign	_	_	
29-18	4365-4373	prostate	_	_	
29-19	4374-4381	disease	_	_	
29-20	4381-4382	.	_	_	

#Text=The optimal combined utilization of the urethra inserted radiating energy microwave source, the circulation cooling fluid in the urethra, the positioning and urine drainage system of the Foley catheter, and the microwave radiometry provides a very practical method to treat benign prostate disease.
30-1	4383-4386	The	_	_	
30-2	4387-4394	optimal	_	_	
30-3	4395-4403	combined	_	_	
30-4	4404-4415	utilization	_	_	
30-5	4416-4418	of	_	_	
30-6	4419-4422	the	_	_	
30-7	4423-4430	urethra	_	_	
30-8	4431-4439	inserted	_	_	
30-9	4440-4449	radiating	_	_	
30-10	4450-4456	energy	_	_	
30-11	4457-4466	microwave	_	_	
30-12	4467-4473	source	_	_	
30-13	4473-4474	,	_	_	
30-14	4475-4478	the	_	_	
30-15	4479-4490	circulation	_	_	
30-16	4491-4498	cooling	_	_	
30-17	4499-4504	fluid	_	_	
30-18	4505-4507	in	_	_	
30-19	4508-4511	the	_	_	
30-20	4512-4519	urethra	_	_	
30-21	4519-4520	,	_	_	
30-22	4521-4524	the	_	_	
30-23	4525-4536	positioning	_	_	
30-24	4537-4540	and	_	_	
30-25	4541-4546	urine	_	_	
30-26	4547-4555	drainage	_	_	
30-27	4556-4562	system	_	_	
30-28	4563-4565	of	_	_	
30-29	4566-4569	the	_	_	
30-30	4570-4575	Foley	_	_	
30-31	4576-4584	catheter	_	_	
30-32	4584-4585	,	_	_	
30-33	4586-4589	and	_	_	
30-34	4590-4593	the	_	_	
30-35	4594-4603	microwave	_	_	
30-36	4604-4614	radiometry	_	_	
30-37	4615-4623	provides	_	_	
30-38	4624-4625	a	_	_	
30-39	4626-4630	very	_	_	
30-40	4631-4640	practical	_	_	
30-41	4641-4647	method	_	_	
30-42	4648-4650	to	_	_	
30-43	4651-4656	treat	_	_	
30-44	4657-4663	benign	_	_	
30-45	4664-4672	prostate	_	_	
30-46	4673-4680	disease	_	_	
30-47	4680-4681	.	_	_	

#Text=It is also feasible that this method will be suitable for the treatment of malignant prostate disease.
31-1	4682-4684	It	_	_	
31-2	4685-4687	is	_	_	
31-3	4688-4692	also	_	_	
31-4	4693-4701	feasible	_	_	
31-5	4702-4706	that	_	_	
31-6	4707-4711	this	_	_	
31-7	4712-4718	method	_	_	
31-8	4719-4723	will	_	_	
31-9	4724-4726	be	_	_	
31-10	4727-4735	suitable	_	_	
31-11	4736-4739	for	_	_	
31-12	4740-4743	the	_	_	
31-13	4744-4753	treatment	_	_	
31-14	4754-4756	of	_	_	
31-15	4757-4766	malignant	_	_	
31-16	4767-4775	prostate	_	_	
31-17	4776-4783	disease	_	_	
31-18	4783-4784	.	_	_	

#Text=The malignant prostate disease normally involves a larger size mass requiring treatment than is possible with the urethra inserted applicators.
32-1	4785-4788	The	_	_	
32-2	4789-4798	malignant	_	_	
32-3	4799-4807	prostate	_	_	
32-4	4808-4815	disease	_	_	
32-5	4816-4824	normally	_	_	
32-6	4825-4833	involves	_	_	
32-7	4834-4835	a	_	_	
32-8	4836-4842	larger	_	_	
32-9	4843-4847	size	_	_	
32-10	4848-4852	mass	_	_	
32-11	4853-4862	requiring	_	_	
32-12	4863-4872	treatment	_	_	
32-13	4873-4877	than	_	_	
32-14	4878-4880	is	_	_	
32-15	4881-4889	possible	_	_	
32-16	4890-4894	with	_	_	
32-17	4895-4898	the	_	_	
32-18	4899-4906	urethra	_	_	
32-19	4907-4915	inserted	_	_	
32-20	4916-4927	applicators	_	_	
32-21	4927-4928	.	_	_	

#Text=However, the increased treatment volume provided by this new method may enable some malignant prostate tumors to be effectively treated as long as the tumor resides within the therapeutic heating area which extends to about 0.8 cm away from the inserted applicator wall.
33-1	4929-4936	However	_	_	
33-2	4936-4937	,	_	_	
33-3	4938-4941	the	_	_	
33-4	4942-4951	increased	_	_	
33-5	4952-4961	treatment	_	_	
33-6	4962-4968	volume	_	_	
33-7	4969-4977	provided	_	_	
33-8	4978-4980	by	_	_	
33-9	4981-4985	this	_	_	
33-10	4986-4989	new	_	_	
33-11	4990-4996	method	_	_	
33-12	4997-5000	may	_	_	
33-13	5001-5007	enable	_	_	
33-14	5008-5012	some	_	_	
33-15	5013-5022	malignant	_	_	
33-16	5023-5031	prostate	_	_	
33-17	5032-5038	tumors	_	_	
33-18	5039-5041	to	_	_	
33-19	5042-5044	be	_	_	
33-20	5045-5056	effectively	_	_	
33-21	5057-5064	treated	_	_	
33-22	5065-5067	as	_	_	
33-23	5068-5072	long	_	_	
33-24	5073-5075	as	_	_	
33-25	5076-5079	the	_	_	
33-26	5080-5085	tumor	_	_	
33-27	5086-5093	resides	_	_	
33-28	5094-5100	within	_	_	
33-29	5101-5104	the	_	_	
33-30	5105-5116	therapeutic	_	_	
33-31	5117-5124	heating	_	_	
33-32	5125-5129	area	_	_	
33-33	5130-5135	which	_	_	
33-34	5136-5143	extends	_	_	
33-35	5144-5146	to	_	_	
33-36	5147-5152	about	_	_	
33-37	5153-5156	0.8	_	_	
33-38	5157-5159	cm	_	_	
33-39	5160-5164	away	_	_	
33-40	5165-5169	from	_	_	
33-41	5170-5173	the	_	_	
33-42	5174-5182	inserted	_	_	
33-43	5183-5193	applicator	_	_	
33-44	5194-5198	wall	_	_	
33-45	5198-5199	.	_	_	

#Text=Certainly if the urethral blockage through the prostate is caused by malignant growth, the use of this method to relieve the blockage symptom is also feasible, even though the intent would possibly not be to cure the cancer if the cancerous growth was larger than the heating volume.
34-1	5200-5209	Certainly	_	_	
34-2	5210-5212	if	_	_	
34-3	5213-5216	the	_	_	
34-4	5217-5225	urethral	_	_	
34-5	5226-5234	blockage	_	_	
34-6	5235-5242	through	_	_	
34-7	5243-5246	the	_	_	
34-8	5247-5255	prostate	_	_	
34-9	5256-5258	is	_	_	
34-10	5259-5265	caused	_	_	
34-11	5266-5268	by	_	_	
34-12	5269-5278	malignant	_	_	
34-13	5279-5285	growth	_	_	
34-14	5285-5286	,	_	_	
34-15	5287-5290	the	_	_	
34-16	5291-5294	use	_	_	
34-17	5295-5297	of	_	_	
34-18	5298-5302	this	_	_	
34-19	5303-5309	method	_	_	
34-20	5310-5312	to	_	_	
34-21	5313-5320	relieve	_	_	
34-22	5321-5324	the	_	_	
34-23	5325-5333	blockage	_	_	
34-24	5334-5341	symptom	_	_	
34-25	5342-5344	is	_	_	
34-26	5345-5349	also	_	_	
34-27	5350-5358	feasible	_	_	
34-28	5358-5359	,	_	_	
34-29	5360-5364	even	_	_	
34-30	5365-5371	though	_	_	
34-31	5372-5375	the	_	_	
34-32	5376-5382	intent	_	_	
34-33	5383-5388	would	_	_	
34-34	5389-5397	possibly	_	_	
34-35	5398-5401	not	_	_	
34-36	5402-5404	be	_	_	
34-37	5405-5407	to	_	_	
34-38	5408-5412	cure	_	_	
34-39	5413-5416	the	_	_	
34-40	5417-5423	cancer	_	_	
34-41	5424-5426	if	_	_	
34-42	5427-5430	the	_	_	
34-43	5431-5440	cancerous	_	_	
34-44	5441-5447	growth	_	_	
34-45	5448-5451	was	_	_	
34-46	5452-5458	larger	_	_	
34-47	5459-5463	than	_	_	
34-48	5464-5467	the	_	_	
34-49	5468-5475	heating	_	_	
34-50	5476-5482	volume	_	_	
34-51	5482-5483	.	_	_	

#Text=The use of ultrasound crystal cylinders is also considered feasible with this method which can operate as both energy transmitters as well as ultrasound radiometric temperature sensors.
35-1	5484-5487	The	_	_	
35-2	5488-5491	use	_	_	
35-3	5492-5494	of	_	_	
35-4	5495-5505	ultrasound	_	_	
35-5	5506-5513	crystal	_	_	
35-6	5514-5523	cylinders	_	_	
35-7	5524-5526	is	_	_	
35-8	5527-5531	also	_	_	
35-9	5532-5542	considered	_	_	
35-10	5543-5551	feasible	_	_	
35-11	5552-5556	with	_	_	
35-12	5557-5561	this	_	_	
35-13	5562-5568	method	_	_	
35-14	5569-5574	which	_	_	
35-15	5575-5578	can	_	_	
35-16	5579-5586	operate	_	_	
35-17	5587-5589	as	_	_	
35-18	5590-5594	both	_	_	
35-19	5595-5601	energy	_	_	
35-20	5602-5614	transmitters	_	_	
35-21	5615-5617	as	_	_	
35-22	5618-5622	well	_	_	
35-23	5623-5625	as	_	_	
35-24	5626-5636	ultrasound	_	_	
35-25	5637-5648	radiometric	_	_	
35-26	5649-5660	temperature	_	_	
35-27	5661-5668	sensors	_	_	
35-28	5668-5669	.	_	_	

#Text=In this form, the ultrasonic thermal energy radiated by the tissue within the ultrasound applicator's heating zone will be detected by the ultrasound radiometer.
36-1	5670-5672	In	_	_	
36-2	5673-5677	this	_	_	
36-3	5678-5682	form	_	_	
36-4	5682-5683	,	_	_	
36-5	5684-5687	the	_	_	
36-6	5688-5698	ultrasonic	_	_	
36-7	5699-5706	thermal	_	_	
36-8	5707-5713	energy	_	_	
36-9	5714-5722	radiated	_	_	
36-10	5723-5725	by	_	_	
36-11	5726-5729	the	_	_	
36-12	5730-5736	tissue	_	_	
36-13	5737-5743	within	_	_	
36-14	5744-5747	the	_	_	
36-15	5748-5758	ultrasound	_	_	
36-16	5759-5771	applicator's	_	_	
36-17	5772-5779	heating	_	_	
36-18	5780-5784	zone	_	_	
36-19	5785-5789	will	_	_	
36-20	5790-5792	be	_	_	
36-21	5793-5801	detected	_	_	
36-22	5802-5804	by	_	_	
36-23	5805-5808	the	_	_	
36-24	5809-5819	ultrasound	_	_	
36-25	5820-5830	radiometer	_	_	
36-26	5830-5831	.	_	_	

#Text=This would therefore be equivalent to the microwave urethral inserted applicator, but would operate at ultrasound frequencies.
37-1	5832-5836	This	_	_	
37-2	5837-5842	would	_	_	
37-3	5843-5852	therefore	_	_	
37-4	5853-5855	be	_	_	
37-5	5856-5866	equivalent	_	_	
37-6	5867-5869	to	_	_	
37-7	5870-5873	the	_	_	
37-8	5874-5883	microwave	_	_	
37-9	5884-5892	urethral	_	_	
37-10	5893-5901	inserted	_	_	
37-11	5902-5912	applicator	_	_	
37-12	5912-5913	,	_	_	
37-13	5914-5917	but	_	_	
37-14	5918-5923	would	_	_	
37-15	5924-5931	operate	_	_	
37-16	5932-5934	at	_	_	
37-17	5935-5945	ultrasound	_	_	
37-18	5946-5957	frequencies	_	_	
37-19	5957-5958	.	_	_	

#Text=Various ultrasound cylinders are commonly available such as from The EBL Company of Hartford, Conn.
38-1	5959-5966	Various	_	_	
38-2	5967-5977	ultrasound	_	_	
38-3	5978-5987	cylinders	_	_	
38-4	5988-5991	are	_	_	
38-5	5992-6000	commonly	_	_	
38-6	6001-6010	available	_	_	
38-7	6011-6015	such	_	_	
38-8	6016-6018	as	_	_	
38-9	6019-6023	from	_	_	
38-10	6024-6027	The	_	_	
38-11	6028-6031	EBL	_	_	
38-12	6032-6039	Company	_	_	
38-13	6040-6042	of	_	_	
38-14	6043-6051	Hartford	_	_	
38-15	6051-6052	,	_	_	
38-16	6053-6057	Conn	_	_	
38-17	6057-6058	.	_	_	

#Text=It is preferred that a longitudinal stack of ultrasound crystals be used to enable more flexibility and bending of the inserted crystals.
39-1	6059-6061	It	_	_	
39-2	6062-6064	is	_	_	
39-3	6065-6074	preferred	_	_	
39-4	6075-6079	that	_	_	
39-5	6080-6081	a	_	_	
39-6	6082-6094	longitudinal	_	_	
39-7	6095-6100	stack	_	_	
39-8	6101-6103	of	_	_	
39-9	6104-6114	ultrasound	_	_	
39-10	6115-6123	crystals	_	_	
39-11	6124-6126	be	_	_	
39-12	6127-6131	used	_	_	
39-13	6132-6134	to	_	_	
39-14	6135-6141	enable	_	_	
39-15	6142-6146	more	_	_	
39-16	6147-6158	flexibility	_	_	
39-17	6159-6162	and	_	_	
39-18	6163-6170	bending	_	_	
39-19	6171-6173	of	_	_	
39-20	6174-6177	the	_	_	
39-21	6178-6186	inserted	_	_	
39-22	6187-6195	crystals	_	_	
39-23	6195-6196	.	_	_	

#Text=During radiometry measurements, it is possible that EM noise sources other than the heated tissue, such as fluorescent lights, radio stations, microwave ovens, etc., can interfere with the accurate operation of the EM radiometer.
40-1	6197-6203	During	_	_	
40-2	6204-6214	radiometry	_	_	
40-3	6215-6227	measurements	_	_	
40-4	6227-6228	,	_	_	
40-5	6229-6231	it	_	_	
40-6	6232-6234	is	_	_	
40-7	6235-6243	possible	_	_	
40-8	6244-6248	that	_	_	
40-9	6249-6251	EM	_	_	
40-10	6252-6257	noise	_	_	
40-11	6258-6265	sources	_	_	
40-12	6266-6271	other	_	_	
40-13	6272-6276	than	_	_	
40-14	6277-6280	the	_	_	
40-15	6281-6287	heated	_	_	
40-16	6288-6294	tissue	_	_	
40-17	6294-6295	,	_	_	
40-18	6296-6300	such	_	_	
40-19	6301-6303	as	_	_	
40-20	6304-6315	fluorescent	_	_	
40-21	6316-6322	lights	_	_	
40-22	6322-6323	,	_	_	
40-23	6324-6329	radio	_	_	
40-24	6330-6338	stations	_	_	
40-25	6338-6339	,	_	_	
40-26	6340-6349	microwave	_	_	
40-27	6350-6355	ovens	_	_	
40-28	6355-6356	,	_	_	
40-29	6357-6360	etc	_	_	
40-30	6360-6361	.	_	_	
40-31	6361-6362	,	_	_	
40-32	6363-6366	can	_	_	
40-33	6367-6376	interfere	_	_	
40-34	6377-6381	with	_	_	
40-35	6382-6385	the	_	_	
40-36	6386-6394	accurate	_	_	
40-37	6395-6404	operation	_	_	
40-38	6405-6407	of	_	_	
40-39	6408-6411	the	_	_	
40-40	6412-6414	EM	_	_	
40-41	6415-6425	radiometer	_	_	
40-42	6425-6426	.	_	_	

#Text=It is possible to perform the application of this EM method inside a metallic shielded room to block out many EM sources which would otherwise possibly interfere with the EM radiometry operation.
41-1	6427-6429	It	_	_	
41-2	6430-6432	is	_	_	
41-3	6433-6441	possible	_	_	
41-4	6442-6444	to	_	_	
41-5	6445-6452	perform	_	_	
41-6	6453-6456	the	_	_	
41-7	6457-6468	application	_	_	
41-8	6469-6471	of	_	_	
41-9	6472-6476	this	_	_	
41-10	6477-6479	EM	_	_	
41-11	6480-6486	method	_	_	
41-12	6487-6493	inside	_	_	
41-13	6494-6495	a	_	_	
41-14	6496-6504	metallic	_	_	
41-15	6505-6513	shielded	_	_	
41-16	6514-6518	room	_	_	
41-17	6519-6521	to	_	_	
41-18	6522-6527	block	_	_	
41-19	6528-6531	out	_	_	
41-20	6532-6536	many	_	_	
41-21	6537-6539	EM	_	_	
41-22	6540-6547	sources	_	_	
41-23	6548-6553	which	_	_	
41-24	6554-6559	would	_	_	
41-25	6560-6569	otherwise	_	_	
41-26	6570-6578	possibly	_	_	
41-27	6579-6588	interfere	_	_	
41-28	6589-6593	with	_	_	
41-29	6594-6597	the	_	_	
41-30	6598-6600	EM	_	_	
41-31	6601-6611	radiometry	_	_	
41-32	6612-6621	operation	_	_	
41-33	6621-6622	.	_	_	

#Text=The addition of a shielded room facility to improve the operation of a radiometer is not considered novel, but is well known in the current application of radiometry.
42-1	6623-6626	The	_	_	
42-2	6627-6635	addition	_	_	
42-3	6636-6638	of	_	_	
42-4	6639-6640	a	_	_	
42-5	6641-6649	shielded	_	_	
42-6	6650-6654	room	_	_	
42-7	6655-6663	facility	_	_	
42-8	6664-6666	to	_	_	
42-9	6667-6674	improve	_	_	
42-10	6675-6678	the	_	_	
42-11	6679-6688	operation	_	_	
42-12	6689-6691	of	_	_	
42-13	6692-6693	a	_	_	
42-14	6694-6704	radiometer	_	_	
42-15	6705-6707	is	_	_	
42-16	6708-6711	not	_	_	
42-17	6712-6722	considered	_	_	
42-18	6723-6728	novel	_	_	
42-19	6728-6729	,	_	_	
42-20	6730-6733	but	_	_	
42-21	6734-6736	is	_	_	
42-22	6737-6741	well	_	_	
42-23	6742-6747	known	_	_	
42-24	6748-6750	in	_	_	
42-25	6751-6754	the	_	_	
42-26	6755-6762	current	_	_	
42-27	6763-6774	application	_	_	
42-28	6775-6777	of	_	_	
42-29	6778-6788	radiometry	_	_	
42-30	6788-6789	.	_	_	

#Text=However, where a shielded room is not available, or where other EM sources may be located in the shielded room, it is useful to include an electrically conductive shield or blanket over or around the patient in the treatment area to reduce the effects of these other EM noise sources on the radiometer.
43-1	6790-6797	However	_	_	
43-2	6797-6798	,	_	_	
43-3	6799-6804	where	_	_	
43-4	6805-6806	a	_	_	
43-5	6807-6815	shielded	_	_	
43-6	6816-6820	room	_	_	
43-7	6821-6823	is	_	_	
43-8	6824-6827	not	_	_	
43-9	6828-6837	available	_	_	
43-10	6837-6838	,	_	_	
43-11	6839-6841	or	_	_	
43-12	6842-6847	where	_	_	
43-13	6848-6853	other	_	_	
43-14	6854-6856	EM	_	_	
43-15	6857-6864	sources	_	_	
43-16	6865-6868	may	_	_	
43-17	6869-6871	be	_	_	
43-18	6872-6879	located	_	_	
43-19	6880-6882	in	_	_	
43-20	6883-6886	the	_	_	
43-21	6887-6895	shielded	_	_	
43-22	6896-6900	room	_	_	
43-23	6900-6901	,	_	_	
43-24	6902-6904	it	_	_	
43-25	6905-6907	is	_	_	
43-26	6908-6914	useful	_	_	
43-27	6915-6917	to	_	_	
43-28	6918-6925	include	_	_	
43-29	6926-6928	an	_	_	
43-30	6929-6941	electrically	_	_	
43-31	6942-6952	conductive	_	_	
43-32	6953-6959	shield	_	_	
43-33	6960-6962	or	_	_	
43-34	6963-6970	blanket	_	_	
43-35	6971-6975	over	_	_	
43-36	6976-6978	or	_	_	
43-37	6979-6985	around	_	_	
43-38	6986-6989	the	_	_	
43-39	6990-6997	patient	_	_	
43-40	6998-7000	in	_	_	
43-41	7001-7004	the	_	_	
43-42	7005-7014	treatment	_	_	
43-43	7015-7019	area	_	_	
43-44	7020-7022	to	_	_	
43-45	7023-7029	reduce	_	_	
43-46	7030-7033	the	_	_	
43-47	7034-7041	effects	_	_	
43-48	7042-7044	of	_	_	
43-49	7045-7050	these	_	_	
43-50	7051-7056	other	_	_	
43-51	7057-7059	EM	_	_	
43-52	7060-7065	noise	_	_	
43-53	7066-7073	sources	_	_	
43-54	7074-7076	on	_	_	
43-55	7077-7080	the	_	_	
43-56	7081-7091	radiometer	_	_	
43-57	7091-7092	.	_	_	

#Text=Suitable materials for this shielding blanket are metal screen or mesh, such as that produced by Cleveland Wire Cloth Manufacturing Company of Cleveland, Ohio.
44-1	7093-7101	Suitable	_	_	
44-2	7102-7111	materials	_	_	
44-3	7112-7115	for	_	_	
44-4	7116-7120	this	_	_	
44-5	7121-7130	shielding	_	_	
44-6	7131-7138	blanket	_	_	
44-7	7139-7142	are	_	_	
44-8	7143-7148	metal	_	_	
44-9	7149-7155	screen	_	_	
44-10	7156-7158	or	_	_	
44-11	7159-7163	mesh	_	_	
44-12	7163-7164	,	_	_	
44-13	7165-7169	such	_	_	
44-14	7170-7172	as	_	_	
44-15	7173-7177	that	_	_	
44-16	7178-7186	produced	_	_	
44-17	7187-7189	by	_	_	
44-18	7190-7199	Cleveland	_	_	
44-19	7200-7204	Wire	_	_	
44-20	7205-7210	Cloth	_	_	
44-21	7211-7224	Manufacturing	_	_	
44-22	7225-7232	Company	_	_	
44-23	7233-7235	of	_	_	
44-24	7236-7245	Cleveland	_	_	
44-25	7245-7246	,	_	_	
44-26	7247-7251	Ohio	_	_	
44-27	7251-7252	.	_	_	

#Text=The conductive sheet may be in the form of a metal impregnated paper such as that produced by Zippertubing Company of Los Angeles, Calif., or by International Paper of Tuxedo, N.Y.
45-1	7253-7256	The	_	_	
45-2	7257-7267	conductive	_	_	
45-3	7268-7273	sheet	_	_	
45-4	7274-7277	may	_	_	
45-5	7278-7280	be	_	_	
45-6	7281-7283	in	_	_	
45-7	7284-7287	the	_	_	
45-8	7288-7292	form	_	_	
45-9	7293-7295	of	_	_	
45-10	7296-7297	a	_	_	
45-11	7298-7303	metal	_	_	
45-12	7304-7315	impregnated	_	_	
45-13	7316-7321	paper	_	_	
45-14	7322-7326	such	_	_	
45-15	7327-7329	as	_	_	
45-16	7330-7334	that	_	_	
45-17	7335-7343	produced	_	_	
45-18	7344-7346	by	_	_	
45-19	7347-7359	Zippertubing	_	_	
45-20	7360-7367	Company	_	_	
45-21	7368-7370	of	_	_	
45-22	7371-7374	Los	_	_	
45-23	7375-7382	Angeles	_	_	
45-24	7382-7383	,	_	_	
45-25	7384-7389	Calif	_	_	
45-26	7389-7390	.	_	_	
45-27	7390-7391	,	_	_	
45-28	7392-7394	or	_	_	
45-29	7395-7397	by	_	_	
45-30	7398-7411	International	_	_	
45-31	7412-7417	Paper	_	_	
45-32	7418-7420	of	_	_	
45-33	7421-7427	Tuxedo	_	_	
45-34	7427-7428	,	_	_	
45-35	7429-7432	N.Y	_	_	
45-36	7432-7433	.	_	_	

#Text=The conductive sheet may even be a metal foil sheet which is commonly marketed as aluminum foil.
46-1	7434-7437	The	_	_	
46-2	7438-7448	conductive	_	_	
46-3	7449-7454	sheet	_	_	
46-4	7455-7458	may	_	_	
46-5	7459-7463	even	_	_	
46-6	7464-7466	be	_	_	
46-7	7467-7468	a	_	_	
46-8	7469-7474	metal	_	_	
46-9	7475-7479	foil	_	_	
46-10	7480-7485	sheet	_	_	
46-11	7486-7491	which	_	_	
46-12	7492-7494	is	_	_	
46-13	7495-7503	commonly	_	_	
46-14	7504-7512	marketed	_	_	
46-15	7513-7515	as	_	_	
46-16	7516-7524	aluminum	_	_	
46-17	7525-7529	foil	_	_	
46-18	7529-7530	.	_	_	

#Text=A practical other shielding material is conductive cloth such as that manufactured by Devex S.A. of Denis, Switzerland, or the Hexcel Corporation of Dublin, Calif.
47-1	7531-7532	A	_	_	
47-2	7533-7542	practical	_	_	
47-3	7543-7548	other	_	_	
47-4	7549-7558	shielding	_	_	
47-5	7559-7567	material	_	_	
47-6	7568-7570	is	_	_	
47-7	7571-7581	conductive	_	_	
47-8	7582-7587	cloth	_	_	
47-9	7588-7592	such	_	_	
47-10	7593-7595	as	_	_	
47-11	7596-7600	that	_	_	
47-12	7601-7613	manufactured	_	_	
47-13	7614-7616	by	_	_	
47-14	7617-7622	Devex	_	_	
47-15	7623-7626	S.A	_	_	
47-16	7626-7627	.	_	_	
47-17	7628-7630	of	_	_	
47-18	7631-7636	Denis	_	_	
47-19	7636-7637	,	_	_	
47-20	7638-7649	Switzerland	_	_	
47-21	7649-7650	,	_	_	
47-22	7651-7653	or	_	_	
47-23	7654-7657	the	_	_	
47-24	7658-7664	Hexcel	_	_	
47-25	7665-7676	Corporation	_	_	
47-26	7677-7679	of	_	_	
47-27	7680-7686	Dublin	_	_	
47-28	7686-7687	,	_	_	
47-29	7688-7693	Calif	_	_	
47-30	7693-7694	.	_	_	

#Text=It is best that these sheets be connected (or grounded) to the outer conductor of the interconnecting applicator cable 16 shown in the Figures.
48-1	7695-7697	It	_	_	
48-2	7698-7700	is	_	_	
48-3	7701-7705	best	_	_	
48-4	7706-7710	that	_	_	
48-5	7711-7716	these	_	_	
48-6	7717-7723	sheets	_	_	
48-7	7724-7726	be	_	_	
48-8	7727-7736	connected	_	_	
48-9	7737-7738	(	_	_	
48-10	7738-7740	or	_	_	
48-11	7741-7749	grounded	_	_	
48-12	7749-7750	)	_	_	
48-13	7751-7753	to	_	_	
48-14	7754-7757	the	_	_	
48-15	7758-7763	outer	_	_	
48-16	7764-7773	conductor	_	_	
48-17	7774-7776	of	_	_	
48-18	7777-7780	the	_	_	
48-19	7781-7796	interconnecting	_	_	
48-20	7797-7807	applicator	_	_	
48-21	7808-7813	cable	_	_	
48-22	7814-7816	16	_	_	
48-23	7817-7822	shown	_	_	
48-24	7823-7825	in	_	_	
48-25	7826-7829	the	_	_	
48-26	7830-7837	Figures	_	_	
48-27	7837-7838	.	_	_	
